Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.30Medicamen Organics Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strength in solvency, growth, and profitability, indicating a solid foundation and good earning potential. However, liquidity and efficiency ratios suggest areas needing attention. While the company is growing its revenue and profits impressively, it struggles with converting assets into sales and maintaining sufficient liquid assets to cover its short-term liabilities. Overall, Medicamen Organics is a company with high growth and profitability potential, but it needs to manage its assets and liabilities more efficiently to ensure long-term financial health. There are opportunities for improvement in managing working capital and enhancing operational efficiency.
Health Score : 6.30Medicamen Organics Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strength in solvency, growth, and profitability, indicating a solid foundation and good earning potential. However, liquidity and efficiency ratios suggest areas needing attention. While the company is growing its revenue and profits impressively, it struggles with converting assets into sales and maintaining sufficient liquid assets to cover its short-term liabilities. Overall, Medicamen Organics is a company with high growth and profitability potential, but it needs to manage its assets and liabilities more efficiently to ensure long-term financial health. There are opportunities for improvement in managing working capital and enhancing operational efficiency.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-10.26
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-7.77
P/B RATIO
1.09
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.42
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-8.67
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹25.65 as on Sep 1, 2026.
Growth Score : 9.20The growth ratios indicate strong growth. High revenue growth, operating profit growth, EPS growth, and net income growth rates suggest the company is expanding its business and increasing its profitability. The asset growth rate, however, is concerning. Overall, the company is experiencing robust growth in key areas, indicating positive momentum and future potential.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellent
Asset Growth RatePoorNet Income Growth RateExcellent| Growth Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue Growth Rate | 51.13 | -40.74 |
| Operating Profit Growth Rate | 39.45 | -156.73 |
| Earnings Per Share (EPS) Growth | 13.44 | -195.38 |
| Asset Growth Rate | 54.03 | -12.8 |
| Net Income Growth Rate | 54.58 | -199.26 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -7.77 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 3 | JFL Life Sciences Ltd | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.89 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.60 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Medicamen Organics Ltd. is an Indian pharmaceutical company specializing in manufacturing, trading, and selling a diverse range of pharmaceutical formulations. It offers tablets, capsules, oral liquids, ointments, gels, and powders. The company primarily engages in contract manufacturing, supplying products to government bodies, private hospitals, and pharmacies both domestically and internationally.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Medicamen Organics Ltd's P/E ratio (TTM) is -10.26, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Medicamen Organics Ltd's P/B ratio is 1.09, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Medicamen Organics Ltd's P/S ratio is 1.42, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Medicamen Organics Ltd's PEG ratio is 0.23.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Medicamen Organics Ltd's EV/EBITDA ratio is -8.67.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Medicamen Organics Ltd's ROE is -13.99%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Medicamen Organics Ltd's ROA is -7.26%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Medicamen Organics Ltd's ROCE is -10.66%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Medicamen Organics Ltd's operating margin is -16.57%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Medicamen Organics Ltd's net margin is -17.76%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Medicamen Organics Ltd's current ratio is 1.75.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Medicamen Organics Ltd's debt-to-equity ratio is 0.04.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Medicamen Organics Ltd's interest coverage ratio is -6.44.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Medicamen Organics Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Medicamen Organics Ltd's EPS is -195.38.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹25.65. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1995
Headquarters: Haridwar, Uttarakhand
Core Offerings: Tablets, Capsules, Oral Liquids, Ointments & Gels, Powders
Stock Listing: NSE (MEDIORG), BSE ({bse})
Promoter: Rahul Kumar Jain, Ashutosh Sharma, Mahendra Kumar Sharma
Medicamen Organics Ltd. was incorporated in 1995 as Medicamen Organics Private Limited. Over the years, it expanded its manufacturing capabilities and diversified its product portfolio. In June 2024, the company converted into a Public Limited Company and was subsequently listed on NSE Emerge, India's platform for small and medium enterprises. Today, it continues its focus on contract manufacturing and supply of pharmaceutical products.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Products | 100% | Operating Profit |
Pharmaceutical Formulations: Manufactures a broad spectrum of pharmaceutical formulations including tablets, capsules, oral liquids, dry powders, and external preparations like ointments and gels.
Contract Manufacturing: Specializes in contract manufacturing for domestic and international clients, catering to various therapeutic segments and dosage forms.
Market Reach: Supplies to government institutions, private hospitals, and pharmacies, with a presence in India and select international markets, adhering to stringent quality standards.
Mr. Rahul Kumar Jain (Chairman & Managing Director): An experienced professional in the pharmaceutical industry, he leads the strategic vision and overall operations of Medicamen Organics Ltd. Mr. Ashutosh Sharma (Whole-time Director): An integral part of the management, he contributes significantly to the operational and manufacturing excellence of the company.
No major subsidiaries reported.
No major recent corporate actions on record apart from the recent IPO in June 2024.
The Medicamen Organics Ltd share price today is ₹25.65 on NSE (MEDIORG), as of 26 Sept 2026.
As of 26 Sept 2026, Medicamen Organics Ltd share price is ₹25.65, with previous close ₹25.65. Today's range is ₹25.65 to ₹25.65. The 52-week range is ₹19.10 to ₹32.
As of today, Medicamen Organics Ltd's market cap is ₹32.06 crore (Small Cap).
Medicamen Organics Ltd's current P/E ratio is -10.26, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 36.50.
Medicamen Organics Ltd's current P/B ratio is 1.09.
Medicamen Organics Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Medicamen Organics Ltd's EPS (TTM) is ₹-195.38.
Medicamen Organics Ltd. is an Indian pharmaceutical company specializing in manufacturing, trading, and selling a diverse range of pharmaceutical formulations. It offers tablets, capsules, oral liquids, ointments, gels, and powders. The company primarily engages in contract manufacturing, supplying products to government bodies, private hospitals, and pharmacies both domestically and internationally.
Medicamen Organics Ltd is promoted by Rahul Kumar Jain, Ashutosh Sharma, Mahendra Kumar Sharma, holding 59.73% as of 26 Sept 2026.
Medicamen Organics Ltd is listed on NSE (MEDIORG) and BSE ({bse}). Its next quarterly results are expected on August/September 2024 (Q1 FY25).
Cash Earnings Per Share (Cash EPS)
